Pharmaceutical - Asia-Pacific, Japan

Filter

Current filters:

Asia-PacificJapan

Popular Filters

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

AstraZeneca acquires full control of Japanese subsidiary

AstraZeneca acquires full control of Japanese subsidiary

26-03-2014

Anglo-Swedish drug major AstraZeneca today announced the completion of the purchase of Sumitomo Chemical’s…

Asia-PacificAstraZenecaJapanMergers & AcquisitionsPharmaceutical

Otsuka’s Samsca, first ADPKD therapy, approved in Japan

25-03-2014

Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24-03-2014

Japanese drug major Astellas Pharma has obtained the marketing approval in Japan of its oral androgen…

Asia-PacificAstellas PharmaJapanMedivationOncologyPharmaceuticalRegulationXtandi

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

Japan’s market for schizophrenia treatment to double by 2022

Japan’s market for schizophrenia treatment to double by 2022

12-03-2014

Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade,…

Asia-PacificJapanMarkets & MarketingNeurologicalPharmaceutical

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

10-03-2014

Japanese drug major Daiichi Sankyo has updated on the H5N1 influenza vaccine project, revealing that…

Asia-PacificDaiichi SankyoJapanPharmaceuticalProductionVaccines

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Novartis gets fourth indication, DME, for Lucentis in Japan

24-02-2014

Swiss drug major Novartis says it has received approval from Japanese regulatory bodies for a fourth…

Asia-PacificJapanLucentisNovartisOphthalmicsPharmaceuticalRegulation

Takeda re-aligns marketing system in Japan

24-02-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it decided to re-align its marketing system in…

Asia-PacificJapanManagementMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Company Spotlight

ImmunoGen

ImmunoGen

Back to top